A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : cCR / clinical complete response

[Related PubMed/MEDLINE]
Total Number of Papers: 163
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   cCR  (>> Co-occurring Abbreviation)
Long Form:   clinical complete response
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study. EUS, FNA, nCRT, pCR, PET-CT, SCC
2020 Cost-Effectiveness and Quality-Adjusted Survival of Watch-and-Wait after Complete Response to Chemoradiotherapy for Rectal Cancer. APR, CI, CRT, CSS, LAR, QALYs, TME, WW
2020 Current Status of "Watch-and-Wait" Rectal Cancer Treatment in Asia-Pacific Countries. APFCP, nCRT
2020 Long-Term Patient-Reported Outcomes After High-Dose Chemoradiation Therapy for Nonsurgical Management of Distal Rectal Cancer. CRT, NSM, PROs, QOL
2020 PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer. MSI-H
2020 Role of radiotherapy in the treatment of rectal cancer in older patients. CXB, EBRT, HDREBT
2020 [Application of imaging diagnosis in watch and wait strategy for locally advanced rectal cancer patients after neoadjuvant therapy]. nCRT, pCR
2020 [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy]. CCRT, DMFS, IMRT, LARC, LRFS, LRR, nCRT, OS, SPR, TME
2020 [Consensus on the Watch and Wait policy in rectal cancer patients after neoadjuvant treatment (2020 version)]. ypCR
10  2020 [Guiding significance of pathological diagnosis in watch and wait strategy for locally advanced rectal cancer patients after neoadjuvant therapy]. cfDNA, CTCs, nCRT
11  2020 [Role of radiotherapy in watch and wait strategy after neoadjuvant trerapy for rectal cancer]. LARC, TME
12  2020 [Thoughts on the watch and wait strategy of patients with rectal cancer after neoadjuvant therapy]. ---
13  2019 A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO). DFS, ESCC, ESOPRESSO
14  2019 Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study. nCRT, OS, PFS
15  2019 An expansion study of genotype-driven weekly irinotecan and capecitabine in combination with neoadjuvant radiotherapy for locally advanced rectal cancer with UGT1A1 *1*1 genotype. MTD, nCRT, pCR, UGT1A1
16  2019 Association of Menopausal Status, Expression of Progesterone Receptor and Ki67 to the Clinical Response to Neoadjuvant Chemotherapy in Luminal Breast Cancer. ER, FISH, HER2, IHC, pCR, PR, ROC
17  2019 Clinical Implications of Conversion Surgery After Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma. ---
18  2019 Definitive radiotherapy or chemoradiotherapy for distal rectal cancer with early stage of cT1-2N0. DMFS, LRFS, OS, PFS
19  2019 Delta radiomics for rectal cancer response prediction with hybrid 0.35T magnetic resonance-guided radiotherapy (MRgRT): a hypothesis-generating study for an innovative personalized medicine approach. GTV, MR, MRgRT, RCT
20  2019 Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer. NACT, pCR, RGCIRC
21  2019 Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients. MRI, NAC, pCR, PPV, US
22  2019 Neoadjuvant chemotherapy of capecitabine + epirubicin + cyclophosphamide combination therapy ( 'CEX' therapy) for HER-2 negative breast cancer, as retrospective study in our institute. CRR, NAC, pCR, PS, TN
23  2019 Organ Preservation in Rectal Cancer: The Patients' Perspective. ---
24  2019 Planned organ preservation for early T2-3 rectal adenocarcinoma: A French, multicentre study. CXB, DRE, MRI, nCRT, PRs
25  2019 Predictive factors for response and toxicity after brachytherapy for rectal cancer; results from the HERBERT study. EBRT, HDREBT, SR
26  2019 Salvage surgery for local regrowths in Watch & Wait - Are we harming our patients by deferring the surgery? ChRT, MIS, NDS, RDS, RG
27  2019 Survival Outcomes for Patients With Clinical Complete Response After Neoadjuvant Chemotherapy: Is Omitting Surgery an Option? NCDB, NCT, OS
28  2019 Value of adding dynamic contrast-enhanced MRI visual assessment to conventional MRI and clinical assessment in the diagnosis of complete tumour response to chemoradiotherapy for rectal cancer. AUC, NAT
29  2019 Watch and wait or surgery for clinical complete response in rectal cancer: a need to study both sides. nCRT, NICE
30  2019 ["Watch and wait" strategy after neoadjuvant therapy for rectal cancer: status survey of perceptions, attitudes and treatment selection in Chinese surgeons]. CWWD, DRE, LCRT, nCRT
31  2019 [A Case of Long-Term Clinical Complete Response after Chemotherapy for Locally Advanced Rectal Cancer]. ---
32  2019 [A Patient with Breast Cancer Who Achieved Continued Clinical Complete Response after Systemic Therapy Alone]. ER, FISH, HER2, PgR, TC
33  2019 [An initial exploration of the application of transanal endoscopic microsurgery in rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy]. nCRT, pCR, TEM
34  2019 [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors]. AE, ECOG, LARC, pCR, PR, TME, TNT, TRG
35  2019 [Application value of colonoscopic assessment in "watch and wait" strategy for mid-lower rectal cancer after neoadjuvant chemoradiotherapy]. HIN, nCRT, NR-DFS
36  2019 [Current status and perspectives on "watch and wait" strategy for rectal cancer patients after clinical complete response following neoadjuvant chemoradiation]. QOL
37  2019 [Epirubicina neoadyuvante con o sin docetaxel secuencial en el tratamiento del cancer de mama avanzado: evaluacion de la respuesta patologica completa y tolerabilidad de la quimioterapia]. FEC, LABC, NC, OR, ORR, ORR, pCR
38  2019 [Principle of surgical management for rectal cancer patients with complete clinical response after neoadjuvant therapy]. pCR, TNT
39  2019 [Rational evaluation of the complete response after neoadjuvant therapy in locally advanced mid-low rectal cancer: the pros and cons of "watch and wait" strategy]. pCR, TME
40  2018 A Cost-Effectiveness Analysis of Contact X-ray Brachytherapy for the Treatment of Patients with Rectal Cancer Following a Partial Response to Chemoradiotherapy. CXB, EBRT, QALYs, WWEBRT
41  2018 A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. 5-FU, CI, SCC
42  2018 Are We Predicting Disease Progress of the Rectal Cancer Patients without Surgery after Neoadjuvant Chemoradiotherapy? nCRT, TLE, TME
43  2018 Assessing residual cancer cells using MRI and US after preoperative chemotherapy in primary breast cancer to omit surgery. DCIS, ER, MRI, pCR, US
44  2018 Clinical complete response after chemoradiotherapy for carcinoma of thoracic esophagus: Is esophagectomy always necessary? A systematic review and meta-analysis. CRT, DFS, OS
45  2018 Comparison of Outcome of Esophagectomy Versus Nonsurgical Treatment for Resectable Esophageal Cancer with Clinical Complete Response to Neoadjuvant Therapy. DSS, RFS
46  2018 Delaying surgery after neoadjuvant chemoradiotherapy in rectal cancer has no influence in surgical approach or short-term clinical outcomes. CRT, pCR, TME
47  2018 Do clinical criteria reflect pathologic complete response in rectal cancer following neoadjuvant therapy? CRM, CRT, HDR-BT, pCR, TME
48  2018 Dose Escalation Using Contact X-ray Brachytherapy After External Beam Radiotherapy as Nonsurgical Treatment Option for Rectal Cancer: Outcomes From a Single-Center Experience. CXB
49  2018 Dose-escalated radiotherapy improved survival for esophageal cancer patients with a clinical complete response after standard-dose radiotherapy with concurrent chemotherapy. ---
50  2018 Oncological and Survival Outcomes in Watch and Wait Patients With a Clinical Complete Response After Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Systematic Review and Pooled Analysis. CI
51  2018 Organ Preservation in Rectal Cancer After Chemoradiation: Should We Extend the Observation Period in Patients with a Clinical Near-Complete Response? CRT, LRFR, near cCR, OS
52  2018 Patients who achieved long-term clinical complete response and subsequently terminated multidisciplinary and anti-HER2 therapy for metastatic breast cancer: A case series. HER2
53  2018 Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma. NAC, pCR, TN
54  2018 Pretreatment clinical stage predicts locoregional recurrence in patients with esophageal cancer who achieved a complete clinical response to chemoradiotherapy. dCRT, DRs, ESCC, LR
55  2018 Rate of Clinical Complete Response for 1 Year or More in Bone-Metastatic Breast Cancer after Comprehensive Treatments including Autologous Formalin-Fixed Tumor Vaccine. AFTV
56  2018 Surveillance versus esophagectomy in esophageal cancer patients with a clinical complete response after induction chemoradiation. ---
57  2018 Total neoadjuvant treatment (CAPOX plus radiotherapy) for patients with locally advanced rectal cancer with high risk factors: A phase 2 trial. pCR, TNT
58  2018 Ultrasound-based prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients. cPR, FNR, NACT, NPV, PPV, TN, US
59  2018 [Is esophagectomy necessary for esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy]. CRT, pCR
60  2017 Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80Years Old. OS, RFS
61  2017 Delayed clinical complete response to intensity-modulated radiotherapy in nasopharyngeal carcinoma. FFS, IMRT, LRFFS, NPC, OS
62  2017 Diagnosis and treatment strategy for clinical complete responders after chemoradiotherapy for rectal cancer: is watch-and-wait policy safe? NACRT, TME, WAW
63  2017 Dose escalation using contact X-ray brachytherapy (Papillon) for rectal cancer: does it improve the chance of organ preservation? CXB, EBCRT
64  2017 Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. EGFR, NCI, OS
65  2017 Multicenter Phase 2 Study of Peri-Irradiation Chemotherapy Plus Intensity Modulated Radiation Therapy With Concurrent Weekly Docetaxel for Inoperable or Medically Unresectable Nonmetastatic Gastric Cancer. CCRT, CI, FU
66  2017 Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis. BCS, CR, DFS, DRFS, LRFS, NAC, OR, OS, pCR
67  2017 Organ or sphincter preservation for rectal cancer. The role of contact X-ray brachytherapy in a monocentric series of 112 patients. CRT, CXB, EBRT, LE, pts
68  2017 Survival outcomes of consolidation chemoradiotherapy in esophageal cancer patients who achieve clinical complete response but refuse surgery after neoadjuvant chemoradiotherapy. ESCC, LR, nCRT
69  2017 The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer. HGSOC, IDS, NAC, OS, PFS
70  2017 Wait and see approach for rectal cancer with a clinically complete response after neoadjuvant concurrent chemoradiotherapy. CCRT, DFS, DM, HR, LR, OS, pCR, RR, TME
71  2017 [Outcome of watch and wait strategy or organ preservation for rectal cancer following neoadjuvant chemoradiotherapy: report of 35 cases from a single cancer center]. CSS, nCRT, NR-DFS, OPR, OS, SPR
72  2016 Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? FNRs, FPRs, MGR, MRI, NACT, NPVs, TN, US
73  2016 Definitive Chemoradiotherapy ("Watch-and-Wait" Approach). CRT, pCR
74  2016 Excellent outcome of medical treatment for Kasabach-Merritt syndrome: a single-center experience. HCR, KMS
75  2016 Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer? CRT, ESCC, OS, pCR
76  2016 New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting. MBC, PR, SD, TNBC
77  2016 Wait-and-see treatment strategies for rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis. nCRT, pCR
78  2016 Watch and wait policy after preoperative radiotherapy for rectal cancer; management of residual lesions that appear clinically benign. TEM
79  2016 [A Case of GIST of the Stomach with Long-Term Survival after Multidisciplinary Treatment, Including Four Surgical Resections of Liver Metastases]. GIST
80  2016 [Research hotspot and progress of preoperative chemoradiotherapy for rectal cancer]. 5-FU, CRT
81  2015 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. CI, CTRT, OS, pathCR, TLG
82  2015 Adaptive servo-ventilation therapy for patients with chronic heart failure in a confirmatory, multicenter, randomized, controlled study. ASV, BNP, CHF, GDMT, LVEF, NYHA
83  2015 Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. ---
84  2015 Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques. CC, FNR, MIB, NACT, NPV, pCR
85  2015 Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. CNCT, DFS, INCT, LARC, NOM, pCR, QOL, TME, TNT
86  2015 Predicting complete response: is there a role for non-operative management of rectal cancer? CRT, TME
87  2015 Serial Assessment of Therapeutic Response to a New Radiosensitization Treatment, Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in Patients with Stage I/II Breast Cancer Using Breast Contrast-Enhanced Magnetic Resonance Imaging. BCT, CE, KORTUC II, MRI
88  2015 The prognostic role of TCF4 expression in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy. LARC, nCRT, TCF4, TME
89  2015 [Predictive value of preoperative imaging and postoperative pathology on clinical complete response after neoadjuvant chemoradiation for locally advanced rectal cancer]. ---
90  2015 [Surgical management of patients with pathologic complete response in the primary tumor after neoadjuvant chemotherapy for rectal cancer]. pCR
91  2014 Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). AEC, CI, DCF-R, M1 LYM
92  2014 Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. PTV, SHR
93  2014 Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Bex, CTCL, DLI, mSWAT, ORR, PFS, PR
94  2014 PDCD4 as a predictor of sensitivity to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. PDCD4
95  2014 [Evaluation of current imaging in restaging rectal cancer after neoadjuvant therapy]. pCR
96  2014 [Postoperative pathological staging correlates the prognosis of rectal cancer after neoadjuvant chemoradiotherapy]. DFS, pCR
97  2013 A watch-and-wait approach to the management of rectal cancer. ---
98  2013 Association of immunohistochemically defined molecular subtypes with clinical response to presurgical chemotherapy in patients with advanced breast cancer. GEP, IHC, TNBC
99  2013 Circulating lymphocytes as predictors of sensitivity to preoperative chemoradiotherapy in rectal cancer cases. LARC, nCRT, TRG
100  2013 Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome. CRT, RT